Meticulous Research® Unveils Comprehensive Global Epigenetics Market Report Forecasting Growth to $5.47 Billion by 2030

[Redding, California - Feb 27, 2024] - Meticulous Research®, a premier global market research company, has released its latest research report, titled 'Epigenetics Market by Offering (Kits, Reagents, Instruments, Software), Method (DNA Methylation, PCR, Chromatin Analysis, Histone, RNA Modification), Application (Oncology, Non-oncology), End User (Pharma, Academics, Hospitals) - Global Forecast to 2030.'

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5628

The global epigenetics market is anticipated to witness substantial growth, reaching $5.47 billion by 2030 at a remarkable CAGR of 15.7%, according to the insights presented in this publication. The driving forces behind this surge include the escalating prevalence of chronic diseases, a surge in the aging population, the global rise in cancer cases, augmented pharmaceutical R&D expenditures, a heightened focus on epigenetics in drug discovery and development, and the decreasing costs associated with genome sequencing. Nonetheless, the market faces challenges stemming from a scarcity of skilled professionals.

The expanding applications of epigenetics in non-oncology diseases, coupled with government support for large-scale genomic sequencing projects, are poised to create lucrative growth opportunities for stakeholders. However, standardization concerns related to epigenetics procedures and the limited applications in toxicology present notable obstacles to market expansion.

Key Players in the Epigenetics Market

Leading the charge in the global epigenetics market are key players such as Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), and other prominent entities, including New England Biolabs, Epigentek Group Inc., Pacific Biosciences of California Inc., Bio-Rad Laboratories, Inc., PerkinElmer, Inc., 10X Genomics, Inc., Active Motif, and Zymo Research Corporation.

Request Sample Report Here @https://www.meticulousresearch.com/request-sample-report/cp_id=5628

Epigenetics Market: Future Outlook

This comprehensive report segments the global epigenetics market by offering (Kits & Reagents, Services, Software), method (DNA Methylation, Histone Modification, RNA Modification, PCR, Chromatin Analysis, Sonication, and Other Methods), application (Oncology, Non-oncology), and end user (Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, Hospitals & Diagnostic Laboratories). The study also provides a detailed analysis of industry competitors and their market share at both global and regional levels.

Key Highlights:

Offerings Segment: In 2023, the kits & reagents segment is poised to dominate the market, with the kits & assays sub-segment expected to exhibit the highest CAGR. This growth is attributed to the repetitive use of kits & assays and advancements in sequencing, mi-RNA, and real-time PCR technologies, enhancing research and disease diagnosis.

Method Segment: The DNA methylation segment is projected to hold the largest share in 2023, with the high-resolution melt (HRM) analysis sub-segment anticipated to experience the highest CAGR. HRM analysis, as a next-generation application of amplicon melting analysis, contributes to the segment's growth through its ability to identify small variations in nucleic acid sequences.

Customize Report @ https://www.meticulousresearch.com/request-customization/cp_id=5628

Application Segment: The oncology segment is forecasted to dominate in 2023, driven by the global burden of cancer, government initiatives, and advancements in cancer research. Epigenetics plays a crucial role in differentiating nuclear organization, DNA methylation, and histone modification patterns between cancer and normal cells.

End User Segment: The pharmaceutical and biotechnology companies segment is expected to lead in 2023, owing to increased demand for research-related products, rising R&D expenditures, technological advancements, and the introduction of new epigenetics products for chronic and rare diseases.

Regional Outlook: Asia-Pacific is anticipated to register the highest CAGR during the forecast period, fueled by government initiatives for genetic diseases, growing cancer incidence, a rising geriatric population, increased R&D spending, and a surge in healthcare expenditure.

Quick Buy @ https://www.meticulousresearch.com/Checkout/10022421

This research report offers a thorough analysis of major geographies, providing comprehensive insights into North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), Latin America, and the Middle East & Africa.

Office No-202, 203,204,205,206 2nd Floor, Pushpak Business Hub, Wakad, , India.

About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

This release was published on openPR.